Leading the Way in Life Science Technologies

GEN Exclusives

More »

New Products

More »
July 1, 2017 (Vol. 37 , No. 13)

Trastuzumab-Binding Protein for ADC Monitoring

Click Image To Enlarge +

Orla Protein Technologies

Orla presents ORLA254, a new trastuzumab-binding protein for simplified assay of trastuzumab binding to its antigen during development and manufacture of antibody-drug conjugates (ADCs). This protein incorporates the Her2 antigen into Orla’s proprietary surface binding unit (SBU). The trastuzumab-binding protein has been specially designed to meet this requirement and incorporates easy immobilization and application across multiple platforms, such as ELISA, and bioanalytical instruments, such as Biacore and Octet. The product is available as a solution or as precoated ELISA plates. Either format enables scientists to quickly and easily test the effect of reaction conditions on the ability of processed trastuzumab to bind its target antigen.

  • Orla Protein Technologies
  • Biomedicine West Wing, International ?Centre for Life
  • Times Square
  • Newcastle upon Tyne , NE1 4EP
  • UNITED KINGDOM

Related To This Company